Usefulness of Topical Imiquimod 3.75% in Cytokeratin 7 Positive Extramammary Paget Disease of the Vulva: Towards Personalized Therapy

Sara Mazzilli; Annunziata Dattola; Anna Angela  Criscuolo; Terenzio  Cosio; Luca  Bianchi; Elena  Campione; Monia  Di Prete; Elisabetta  Botti

doi:10.5826/dpc.1102a11

Usefulness of Topical Imiquimod 3.75% in Cytokeratin 7 Positive Extramammary Paget Disease of the Vulva: Towards Personalized Therapy

Authors

Sara Mazzilli Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Italy
Annunziata Dattola Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Italy
Anna Angela Criscuolo Gynecology Department, University of Rome Tor Vergata, Italy
Terenzio Cosio Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Italy
Luca Bianchi Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Italy
Elena Campione Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Italy
Monia Di Prete Anatomical Pathology, University of Rome Tor Vergata, Italy
Elisabetta Botti Department of Gynecology, University of Rome Tor Vergata, Italy

Keywords:

imiquimod, extramammary Paget disease, vulva, cytokeratin 7

References

St Claire K, Hoover A, Ashack K, Khachemoune A. Extramammary Paget disease. Dermatol Online J. 2019;25(4):13030/qt7qg8g292. PMID: 31046904.

Damavandy AA, Terushkin V, Zitelli JA, et al. Intraoperative immunostaining for cytokeratin-7 during Mohs micrographic surgery demonstrates low local recurrence rates in extramammary Paget's disease. Dermatol Surg. 2018;44(3):354-364. DOI: 10.1097/DSS.0000000000001355. PMID: 29517496.